Medtecs International (9103) Fundamentals 2026 — Revenue Analysis | SniperIQ
Medtecs International (9103) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT
Medtecs International (9103) has a market capitalization of approximately NT
Medtecs International's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Medtecs International runs a net profit margin of -6.0%, a gross margin of 15.8%, and an operating margin of -8.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Medtecs International reported revenue of $78M for fiscal year 2025, with net income of -$5M and earnings per share (EPS) of -0.0089. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Medtecs International does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Medtecs International carries a debt-to-equity ratio of 0.21x and a current ratio of 1.94x, with a market beta of 0.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medtecs International (9103) the key facts are: market cap NT
Get Medtecs International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.